Abstract
Endometrial cancer is the most common gynaecological cancer, and is associated with endometrial hyperplasia, unopposed oestrogen exposure and adjuvant therapy for breast cancer using selective oestrogen-receptor modulators (SERMs), particularly tamoxifen. Oestrogen and SERMs are thought to be involved in endometrial carcinogenesis through their effects on transcriptional regulation. Ultimately, oestrogen and SERMs affect the transduction of cellular signalling pathways that govern cell growth and proliferation, through downstream effectors such as PAX2 (paired box 2).
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Cell Transformation, Neoplastic / drug effects*
-
Cell Transformation, Neoplastic / pathology
-
Endometrial Neoplasms / chemically induced*
-
Endometrial Neoplasms / pathology
-
Estrogens / adverse effects*
-
Estrogens / pharmacology
-
Female
-
Humans
-
PAX2 Transcription Factor / genetics
-
PAX2 Transcription Factor / metabolism
-
Selective Estrogen Receptor Modulators / adverse effects*
-
Selective Estrogen Receptor Modulators / pharmacology
Substances
-
Estrogens
-
PAX2 Transcription Factor
-
Selective Estrogen Receptor Modulators